Hanmi Pharmaceutical Reports 362.3 Billion Won in Sales and 55.1 Billion Won in Operating Profit for Q3

Net profit of 45.4 billion won, up 29.9% year-on-year

Hanmi Pharmaceutical achieved cumulative sales of 1.1146 trillion won within three quarters, driven by the growth of its main products-incrementally improved and combination drugs-and the strong performance of its Chinese subsidiary, Beijing Hanmi Pharmaceutical.

Seoul Songpa-gu Hanmi Pharm Headquarters view. Hanmi Pharm

On October 30, Hanmi Pharmaceutical announced its provisional consolidated results for the third quarter of this year, reporting sales of 362.3 billion won, operating profit of 55.1 billion won, and net profit of 45.4 billion won. Compared to the same period last year, operating profit and net profit increased by 8.0% and 29.9%, respectively. The solid growth of incrementally improved and combination drugs, as well as the upfront payment received from the technology transfer agreement for "Ensacuita" signed with Gilead Sciences, are credited for the improved profitability.

In particular, third-quarter outpatient prescription sales (based on UBIST reimbursement criteria) reached 256.5 billion won, up 3.0% year-on-year. The combination drug for dyslipidemia, "Rosuzet," recorded third-quarter outpatient prescription sales of 58.9 billion won, a 10.1% increase from the same period last year. The antihypertensive product group "Amozaltan Family" recorded 37 billion won, and the gastroesophageal reflux disease product group "Esomezol Family" recorded 15.7 billion won in sales. The new diabetes product "Daparon Family" saw a 58.7% year-on-year increase, making it a strong contender for blockbuster status.

Several new products were also launched in the third quarter. The world's first low-dose triple antihypertensive "Amoprel," the osteoporosis treatment "Obodens," and the injectable influenza treatment "Hanmi Peramivir Injection" are expected to drive future sales growth. Hanmi Pharmaceutical plans to further strengthen its combination drug strategy focusing on hypertension, dyslipidemia, and diabetes, while continuing to expand its brand power across various therapeutic areas such as cardiovascular, urology, and bone metabolism.

In the R&D sector, significant achievements have been made in new drug development through the obesity drug project "H.O.P." The project's leading candidate, "Efeglenatide," demonstrated excellent efficacy and safety in the interim topline results of its Phase 3 clinical trial. The company has set commercialization targets for its next-generation triple-action obesity treatment (LA-GLP/GIP/GCG, HM15275) and innovative obesity treatment (LA-UCN2, HM17321) for 2030 and 2031, respectively, and is accelerating clinical development by focusing all organizational capabilities.

Beijing Hanmi Pharmaceutical, the Chinese subsidiary, posted consolidated third-quarter sales of 94.1 billion won, operating profit of 23.6 billion won, and net profit of 21.2 billion won. Compared to the same period last year, sales and operating profit increased by 11.6% and 57.6%, respectively, showing double-digit growth. Sales of digestive products, including the children's probiotic "Mamiai" and the adult probiotic "Maechangan," continue to expand steadily.

Park Jaehyun, CEO of Hanmi Pharmaceutical, stated, "The third quarter was a meaningful period in which the solid growth of innovative products developed with Hanmi's proprietary technology and progress in global new drug clinical development further strengthened our fundamentals. Going forward, we will expand our global presence based on Hanmi's brand competitiveness and further enhance the future value of our new drug pipeline to meet the expectations and support of our shareholders."